Searching On:

Disease:

Gene:

MAP2K1 (MEK1), MAP2K1 (MEK) -

View:
Expand Collapse No disease selected  - General Description
Mass General Hospital Cancer Center treats patients with many cancer types. To learn more about the different cancer types that can be treated at the Cancer Center, please visit the Cancer Center website at the following page: http://www.massgeneral.org/cancer/services/
Expand Collapse MAP2K1 (MEK1)  - General Description The MAP2K1 gene encodes for a protein known as MEK1 protein kinase. This protein is part of a signaling pathway known as the MAP kinase cascade that relays chemical signals from outside the cell to the cell's nucleus and helps control various cellular processes, including cell proliferation, cell differentiation and cell death. MAP2K1 is very similar to the gene MAP2K2 (endoding the protein MEK2 protein kinase), which is also part of the same pathway. Both the MEK1 and the MEK2 protein kinases seem to be essential for normal development and survival before and after birth. Mutations in MAP2K1 have been identified in lung cancer, colon cancer and melanoma of the skin. Since MEK1 is a link in the middle of the MAP kinase cascade, drugs that block its action may be effective in treating cancers caused by defective genes that affect links in the first part of this pathway, such as activating mutations in BRAF, KRAS and NRAS. Source: Genetics Home ReferenceThe MAP2K1 (MEK1) gene encodes for a serine/threonine kinase component of the MAP kinase cascade, which regulates multiple cellular processes including proliferation, survival and differentiation. Mutations in MEK1 have been described at low prevalence in lung cancer, colon cancer, melanoma and ovarian cancer cell lines. Source: Genetics Home Reference
CLICK IMAGE FOR MORE INFORMATION
The MAP2K1 gene encodes for a protein known as MEK1 protein kinase. This protein is part of a signaling pathway known as the MAP kinase cascade that relays chemical signals from outside the cell to the cell's nucleus and helps control various cellular processes, including cell proliferation, cell differentiation and cell death. MAP2K1 is very similar to the gene MAP2K2 (endoding the protein MEK2 protein kinase), which is also part of the same pathway. Both the MEK1 and the MEK2 protein kinases seem to be essential for normal development and survival before and after birth.

Mutations in MAP2K1 have been identified in lung cancer, colon cancer and melanoma of the skin. Since MEK1 is a link in the middle of the MAP kinase cascade, drugs that block its action may be effective in treating cancers caused by defective genes that affect links in the first part of this pathway, such as activating mutations in BRAF, KRAS and NRAS.

Source: Genetics Home Reference
The MAP2K1 (MEK1) gene encodes for a serine/threonine kinase component of the MAP kinase cascade, which regulates multiple cellular processes including proliferation, survival and differentiation. Mutations in MEK1 have been described at low prevalence in lung cancer, colon cancer, melanoma and ovarian cancer cell lines.

Source: Genetics Home Reference
PubMed ID's
18632602, 19411838, 18060073
Expand Collapse MAP2K1 (MEK) -  in MAP2K1 (MEK1)

Share with your Physican

Print information for your Physician.

Print information

Your Matched Clinical Trials

Trial Matches: (G) - Gene, (M) - Mutation
Trial Status: No record found.
Protocol # Title Location Status Match
MGH has many open clinical trials for other cancers not shown on the Targeted Cancer Care website. They can be found on the MassGeneral.org clinical trials search page.

Additional clinical trials may be applicable to your search criteria, but they may not be available at MGH. These clinical trials can typically be found by searching the clinicaltrials.gov website.
There are currently no clinical trials available for your selection. New clinical trials are being approved every day. Please continue to check back for updates.
Trial Status: No record found.

Share with your Physican

Print information for your Physician.

Print information